Skip to content

Partnerships

University of Auckland

Proacta currently conducts all its preclinical research work at the University of Auckland, and holds an exclusive worldwide license for all intellectual property developed through this research in the field of hypoxia activated prodrugs for the treatment of cancer.

Back to top

  • Alta Partners
  • Cancer Society
  • Clarus
  • Delphi Ventures
  • Endeavour Capital
  • GBS
  • Genentech
  • No. 8 Ventures
  • Roche
  • UniServices
  • The University of Auckland